Form 4: Compass Therapeutics Director James P. Boylan Acquires 40,000 Stock Options

Director James P. Boylan of Compass Therapeutics acquires 40,000 stock options with an exercise price of $3.65 on February 11, 2025.

Summary

• On February 11, 2025, James P. Boylan, a director of Compass Therapeutics, acquired 40,000 stock options.
• The exercise price for these options is $3.65.
• The options vest over 48 months, starting March 11, 2025.
• The options expire on February 11, 2035.
• Boylan is obligated to transfer any securities or economic benefits from these options to Enavate Sciences, LP.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and align the interests of management with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors and executives in the biotechnology industry.
• The vesting schedule of 48 months is also a common practice to ensure long-term commitment.
• Comparable companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their compensation packages.

Stakeholder Impact

• The acquisition of stock options by a director can align their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates